On November 4, 2016, Arno Therapeutics, Inc. (OTCPK:ARNI) closed the transaction. The company has issued 1,214,999 units for gross proceeds $425,250 in its last tranche. The company has issued 7,787,136 shares for gross proceeds of $2,725,498.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0003 USD | +417.24% | -.--% | +200.00% |
2017 | Arno Therapeutics, Inc. Terminates Licensing Agreement with Ohio State University | CI |
2017 | Arno Therapeutics Seeks Acquisitions | CI |
1st Jan change | Capi. | |
---|---|---|
+200.00% | 14.8T | |
-2.99% | 8.95TCr | |
+2.24% | 4.07TCr | |
-12.92% | 3.32TCr | |
+61.72% | 2.65TCr | |
-19.87% | 1.47TCr | |
-7.77% | 1.29TCr | |
-12.64% | 1.15TCr | |
-42.60% | 1.13TCr | |
+4.27% | 884.15Cr |
- Stock Market
- Equities
- ARNI Stock
- News Arno Therapeutics, Inc.
- Arno Therapeutics, Inc. announced that it has received $2.725498 million in funding from Pontifax Ltd., OPKO Health, Inc., Perceptive Advisors LLC, Commercial Street Capital, LLC, Bonderman Family Limited Partnership, Auriga Capital Management, LLC